⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of EIPICO and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
EIPICO
↗10th of Ramadan City, Egypt
EIPICO is the leading pharmaceutical manufacturer in Egypt and a major player in the MENA region, established in 1980. The company specializes in the production of a wide range of pharmaceutical products, including antibiotics, lyophilized products, and spansule capsules, operating extensive manufacturing facilities in 10th of Ramadan City.
EIPICO is currently expanding its capabilities into biotechnology and biosimilars through its 'EIPICO 3' facility, which is designed to be the first of its kind in Egypt to manufacture biological products from the cell line to the final dosage form. The company maintains a strong international presence, exporting to over 60 countries, and is publicly listed on the Egyptian Exchange (EGX).
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$100M-$200M
Founded:1980
Ownership:public
Status:operating
STOCK
Exchange:Egyptian Exchange (EGX)
Ticker:PHAR
Market Cap:$0.29B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Commercial/Biosimilar development
Modalities:Small molecule, Biosimilars, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Egyptian International Company for Ampoules (EIACO), Arab Pharmaceutical Services Company (Arab API)
Key Partnerships:Pharmadule (Morimatsu Industry Group) for modular manufacturing, Reliance Life Sciences for biosimilar development
COMPETITION
Position:Leader
Competitors:EVA Pharma, Amoun Pharmaceutical Company, Pharco Pharmaceuticals, October Pharma
LEADERSHIP
Key Executives:
Khaled Salah Hagag - CEO
LINKS
Website:eipico.net
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with EIPICO. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.